Collegium Pharmaceutical, Inc
COLL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267565
No open-market purchases or sales by Collegium Pharmaceutical, Inc insiders were filed in the last 90 days; 279 institutions reported holding it in 13F filings for Q2 2026, worth $1.42B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Collegium Pharmaceutical, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Collegium Pharmaceutical, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Santini Gino | Director | 112,483 | Jun 10, 2026 | 2 |
| Freund John Gordon | Director | 83,952 | May 20, 2026 | 2 |
| Bohlin Garen G | Director | 71,000 | May 18, 2026 | 2 |
| Lurker Nancy | Director | 26,758 | May 18, 2026 | 2 |
| Paya Carlos V | Director | 28,323 | May 18, 2026 | 1 |
| Balice-Gordon Rita J. | Director | 61,370 | May 18, 2026 | 2 |
| Glancy Donovan Michael | Director | 17,482 | May 18, 2026 | 1 |
| Dieter David | EVP & General Counsel | 68,231 | Apr 3, 2026 | 4 |
| Dreyer Scott | EVP & Chief Commercial Officer | 71,770 | Mar 5, 2026 | 3 |
| Karnani Vikram | President and CEO | 197,864 | Feb 12, 2026 | 2 |
| Smith Thomas B | EVP and Chief Medical Officer | 90,651 | Feb 12, 2026 | 1 |
| Tupper Colleen | EVP & Chief Financial Officer | 147,282 | Feb 12, 2026 | 2 |
| Fallon John A. | Director | 64,634 | Nov 14, 2025 | 1 |
| Rubric Capital Management LP | 10% Owner | 3,132,743Indirect | Aug 15, 2025 | 0 |
| Rosen David Efraim | 10% Owner | 3,132,743Indirect | Aug 15, 2025 | 0 |
| Kuhlmann Shirley R. | EVP and General Counsel | 108,137 | Mar 6, 2025 | 0 |
| Heffernan Michael Thomas | Director | 50,328 | Feb 12, 2025 | 0 |
| Melincoff Gwen A | Director | 52,468 | May 16, 2024 | 0 |
| McFarlane Neil F. | Director | 49,365 | May 16, 2024 | 0 |
| Ciaffoni Joseph | President and CEO | 444,867 | Feb 14, 2024 | 0 |
| Malamut Richard | EVP and Chief Medical Officer | 130,264 | Feb 14, 2022 | 0 |
| Fleming Alison B | EVP & Chief Technical Officer | 143,694 | Aug 12, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 (view filing) | Aug 18 | 2 days | Dreyer ScottEVP & Chief Commercial Officer | SSale | −16.4K | $38.21 | −$626.2K | −13.7%103.6K after | 10b5-1 |
| Sep 3, 2025 (view filing) | Aug 29 | 5 days | Smith Thomas BEVP and Chief Medical Officer | SSale | −17.5K | $38.42 | −$671.5K | −19.9%70.3K after | |
| Nov 7, 2025 (view filing) | Nov 6 | 1 day | Tupper ColleenEVP & Chief Financial Officer | SSale | −30.0K | $40.53 | −$1.22M | −19.1%126.7K after | 2 lots10b5-1 |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Fallon John A.Director | SSale | −34.9K | $47.21 | −$1.65M | −35.0%64.6K after | |
| Dec 9, 2025 (view filing) | Dec 5 | 4 days | Balice-Gordon Rita J.Director | SSale | −3.65K | $47.03 | −$171.7K | −6.5%52.6K after | |
| Dec 10, 2025 (view filing) | Dec 8 | 2 days | Dreyer ScottEVP & Chief Commercial Officer | SSale | −17.6K | $48.17 | −$847.8K | −14.5%103.6K after | 2 lots10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Dreyer ScottEVP & Chief Commercial Officer | SSale | −50.0K | $40.40 | −$2.02M | −41.0%71.8K after | 2 lots10b5-1 |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Dieter DavidEVP & General Counsel | SSale | −6.22K | $36.65 | −$228.1K | −6.4%91.0K after | 10b5-1 |
| Mar 20, 2026 (view filing) | Mar 18 | 2 days | Dieter DavidEVP & General Counsel | SSale | −14.0K | $34.92 | −$488.0K | −15.4%77.1K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11 | 2 days | Bohlin Garen GDirector | SSale | −8.70K | $37.18 | −$323.5K | −12.3%62.3K after | |
| May 15, 2026 (view filing) | May 13 | 2 days | Lurker NancyDirector | SSale | −4.50K | $35.97 | −$161.9K | −20.0%18.0K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Freund John GordonDirector | SSale | −4.13K | $34.54 | −$142.5K | −4.7%84.0K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Freund John GordonDirector | SSale | −20 | $34.05 | −$681 | 0.0%84.0K after |